Evidence map›Paper›PMID 41154599›Full record

ReviewBiomolecules2025

Traditional and New Views on MSI-H/dMMR Endometrial Cancer.

Chuqi Liu, Huiyu Ping, Mengmeng Yao, Xinru Li, Qingxin Li, Ruotong Hu, Yawen Xu, Kaidi Meng, Fei Gao, Kai Meng

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chuqi LiuLin He's Academician Workstation of New Medicine and Clinical Translation, Jining Medical University, Jining 272067, China.
Huiyu PingLin He's Academician Workstation of New Medicine and Clinical Translation, Jining Medical University, Jining 272067, China.
Mengmeng YaoLin He's Academician Workstation of New Medicine and Clinical Translation, Jining Medical University, Jining 272067, China.
Xinru LiLin He's Academician Workstation of New Medicine and Clinical Translation, Jining Medical University, Jining 272067, China.
Qingxin LiLin He's Academician Workstation of New Medicine and Clinical Translation, Jining Medical University, Jining 272067, China.
Ruotong HuLin He's Academician Workstation of New Medicine and Clinical Translation, Jining Medical University, Jining 272067, China.
Yawen XuLin He's Academician Workstation of New Medicine and Clinical Translation, Jining Medical University, Jining 272067, China.
Kaidi MengCollege of Medical Laboratory, Qilu Medical University, Zibo 255300, China.
Fei GaoLin He's Academician Workstation of New Medicine and Clinical Translation, Jining Medical University, Jining 272067, China.
Kai MengLin He's Academician Workstation of New Medicine and Clinical Translation, Jining Medical University, Jining 272067, China.

Funding

College Students' Innovation Training Program of Jining Medical University cx2024096zLin He's Academician Workstation of New Medicine and Clinical Translation in Jining Medical University JYHL2021MS13
6 · The paper itself

Abstract

MSI-H/dMMR endometrial cancer (EC) is closely linked to the mismatch repair (MMR) pathway, and its pathogenesis is associated with microsatellite instability (MSI) caused by abnormalities in the core genes of the conventional MMR system. This cancer exhibits a distinct immune microenvironment, which makes it suitable for treatment with immune checkpoint inhibitors (ICIs). This cancer type demonstrates heterogeneity, encompassing Lynch syndrome (LS)-associated EC (characterized by germline mutations), sporadic EC (attributed to

Indexed as

DNA Mismatch RepairEndometrial NeoplasmsMicrosatellite InstabilityColorectal Neoplasms, Hereditary NonpolyposisDNA MethylationFemaleHumansImmune Checkpoint InhibitorsMutationMutL Protein Homolog 1Tumor MicroenvironmentImmune Checkpoint InhibitorsMutL Protein Homolog 1base mismatch repair pathwayMSI-H/dMMR endometrial cancernext-generation sequencing

Identifiers

PMID41154599
PMCPMC12562029

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.